Orforglipron
ATTAIN-J
Eli Lilly · Phase 3 · Completed · Enrollment 238
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo QD | 15% | 3.33% | 0% | 0% |
| 6 mg Orforglipron QD | 45.9% | 18.03% | 9.84% | 3.28% |
| 12 mg Orforglipron QD | 61.4% | 35.09% | 22.81% | 12.28% |
| 36 mg Orforglipron QD | n/r | n/r | n/r | n/r |
Not shown
- 36 mg Orforglipron QD: endpoint not reported